Free Trial

Spectral Medical Q2 2024 Earnings Report

Spectral Medical logo
C$0.77 0.00 (0.00%)
As of 01:05 PM Eastern

Spectral Medical EPS Results

Actual EPS
-C$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Spectral Medical Revenue Results

Actual Revenue
$0.47 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Spectral Medical Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Remove Ads

Spectral Medical Earnings Headlines

Spectral Medical Full Year 2024 Earnings: Beats Expectations
Elon Set to Shock the World by May 1st ?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.
Stocks in play: Spectral Medical Inc.
Spectral Medical Advances Amid Tigris Trial Challenges
The top TSX healthcare stocks under $1
See More Spectral Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Spectral Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spectral Medical and other key companies, straight to your email.

About Spectral Medical

Spectral Medical (TSE:EDT) Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. The segments of the group are Spectral Medical Inc, which is the key revenue-generating segment that manufactures and sells its EAA diagnostic and certain proprietary reagents; Dialco Medical Inc segment; and Corporate.

View Spectral Medical Profile

More Earnings Resources from MarketBeat